SCI-PUB

Non-Hodgkin's Lymphomas

Infections in lymphoma patients treated with bispecific antibodies: A systematic review and meta-analysis.

No abstract text is available for this article

DOI: 10.1182/bloodadvances.2024012916

Reynolds G, Maclean M, Cliff ERS, Teh BW, Thursky KA, Slavin MA, Anderson MA, Hawkes EA

Blood advances, 2024-04-18

Application of machine learning in the management of lymphoma: Current practice and future prospects.

In the past decade, digitization of medical records and multiomics data analysis in lymphoma has led to the accessibility of high-dimensional records...

DOI: 10.1177/20552076241247963

Yuan J, Zhang Y, Wang X

Digital health, 2024-04-18

Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.

Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE)...

DOI: 10.1002/psp4.13141

Deng R, Gibiansky L, Lu T, Flowers CR, Sehn LH, Liu Q, Agarwal P, Liao MZ, Dere R, Lee C, Man G, Hirata J, Li C, Miles D

CPT: pharmacometrics & systems pharmacology, 2024-04-17

The impact of race and ethnicity on diffuse large B-cell lymphoma outcomes within the veterans health administration (VHA).

We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021...

DOI: 10.1080/10428194.2024.2338856

Ta A, Kaur S, Mader M, Franklin K, Williams M, Williams R, Blaize JP, Naqvi A, Ananth S, Song M, Warnecke BO, Pandya A, Djoumessi LRD, Nazarewicz P, Espinoza-Gutarra M, Lucero KT, Whitehead J, Al-Abayechi A, Boyle L, Lee S, Roman Souza G, Toro Velez

Leukemia & lymphoma, 2024-04-17

Higher Mortality in Patients With Diffuse Large B-cell Lymphoma Pre-Existing Arterial Hypertension-Real World Data of the Polish Lymphoma Research Group.

In the long-term follow-up of patients with DLBCL, the role of AH, as an important age-independent predictor of premature cardiovascular mortality, was so strong that it may have value for use in close surveillance in cardio-oncology clinics.

DOI: 10.1016/j.hlc.2024.03.003

Szmit S, Długosz-Danecka M, Drozd-Sokołowska J, Joks M, Szeremet A, Jurczyszyn A, Jurczak W

Heart, lung & circulation, 2024-04-16

Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trial.

Using PTCy and short-term Everolimus is safe with low rates of aGvHD and no severe aGvHD or cGvHD translating into a low rate of non-relapse mortality. Our results in this difficult to treat patient population are encouraging and warrant further studies.

DOI: 10.1111/ejh.14210

Richardson T, Scheid C, Herling M, Frenzel LP, Herling C, Aguilar MRC, Theurich S, Hallek M, Holtick U

European journal of haematology, 2024-04-16

Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.

Our results indicate that the combination of chidamide and PD-1 blockade as maintenance therapy could improve the outcomes of aggressive LBCL patients at high risk of failing CAR-T cell therapy.

DOI: 10.1016/j.intimp.2024.112014

Wang Z, Xu H, Mei Y, Xiao M, Cao Y, Huang L, Yang Z, Zhang Y, Han Z, Zheng M, Hong Z

International immunopharmacology, 2024-04-16

A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy.

CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown promising initial complete remission (CR) rates in patients with refractory or relapsed (r/r) T-cell acute lymphoblastic leukaemia and lymphoblastic lymphoma (T-ALL/LBL)...

DOI: 10.1111/bjh.19445

Cao XY, Zhang JP, Lu Y, Zhao YL, Liu DY, Xiong M, Sun RJ, Wei ZJ, Zhou JR, Zhang X, Yang JF, Li J, Lu P

British journal of haematology, 2024-04-15

Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.

This study identified a novel prognostic panel of CREB1, N4BP1, DEAF1, and UBAP2 AAbs that is independent of the IPI in DLBCL.

DOI: 10.1002/cncr.35158

Dai L, Chen H, Tan Q, Wang Y, Li L, Lou N, Fan G, Xie T, Luo R, Wang S, Zhou Y, Zhong Q, Yao J, Zhang Z, Tang L, Shi Y, Han X

Cancer, 2024-04-17

Наверх